Deka Bank Deutsche Girozentrale Immuno Gen, Inc. Transaction History

Deka Bank Deutsche Girozentrale

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	BUY	$12.46 - $29.95 $34,850 - $83,770	2,797 Added 4.0%	72,697 $2.15 Million
Q1 2022 Apr 28, 2022	BUY	$4.26 - $7.48 $27,264 - $47,872	6,400 Added 10.08%	69,900 $332,000
Q4 2021 Feb 02, 2022	BUY	$4.75 - $7.5 $7,125 - $11,250	1,500 Added 2.42%	63,500 $473,000
Q4 2020 Mar 12, 2021	BUY	$3.7 - $7.66 $229,400 - $474,920	62,000 New	62,000 $402,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $200,244 - $305,778	-90,200 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$1.8 - $3.3 $63,180 - $115,830	35,100 Added 63.7%	90,200 $185,000
Q1 2019 May 10, 2019	BUY	$2.41 - $5.91 $24,100 - $59,100	10,000 Added 22.17%	55,100 $562,000
Q4 2018 Feb 12, 2019	SELL	$3.94 - $9.7 $39,400 - $97,000	-10,000 Reduced 18.15%	45,100 $201,000
Q3 2018 Nov 09, 2018	SELL	$8.6 - $11.26 $12,900 - $16,890	-1,500 Reduced 2.65%	55,100 $0
Q1 2018 May 03, 2018	BUY	$6.7 - $12.95 $379,220 - $732,970	56,600 New	56,600 $608,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.